We are a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders.

Our clinical stage pipeline includes VTX958, a Phase 2 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2 S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 2 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.